Compare Regeneron Pharmaceuticals Inc (REGN) vs Tilray Brands Inc (TLRY) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.

TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.